BPG is committed to discovery and dissemination of knowledge
Articles in Press
4/3/2026 5:50:21 AM | Browse: 16 | Download: 0
Publication Name World Journal of Gastrointestinal Surgery
Manuscript ID 119941
Country China
Category Gastroenterology & Hepatology
Manuscript Type Retrospective Cohort Study
Article Title Anti-reflux mucosectomy is associated with better short-term symptoms than double-dose proton pump inhibitor in reflux esophagitis patients
Manuscript Source Unsolicited Manuscript
All Author List Wen-Jun Jiang, Jie Liu, Ying-Ling Liu, Meng-Die Tang, Yuan Sheng and Ye-Tao Wang
Funding Agency and Grant Number
Funding Agency Grant Number
Scientific Research Plan Project of Universities in Anhui Province No. 2024AH052045
Corresponding Author Ye-Tao Wang, Chief Physician, Department of Gastroenterology, The First Affiliated Hospital of University of Science and Technology of China (USTC), Division of Life Sciences and Medicine, University of Science and Technology of China, No. 17 Lujiang Road, Hefei 230001, Anhui Province, China. wangyt96@163.com
Key Words Gastroesophageal reflux disease; Anti-reflux mucosectomy; Quality of life; Reflux esophagitis; Proton pump inhibitor
Core Tip Anti-reflux mucosectomy (ARMS) is an innovative endoscopic technique developed for the management of refractory gastroesophageal reflux disease. The procedure aims to induce submucosal fibrosis following mucosectomy at the esophagogastric junction, offering the advantage of a minimally invasive endoscopic approach. Since its inception, multiple prospective and retrospective studies have been conducted to evaluate the clinical outcomes associated with ARMS. In this context, we present the findings of a retrospective cohort study comparing the efficacy of ARMS to twice-daily proton pump inhibitor (PPI) therapy in a well-defined population of patients exhibiting moderate-to-severe regurgitation despite once-daily PPI treatment.
Citation Jiang WJ, Liu J, Liu YL, Tang MD, Sheng Y, Wang YT. Anti-reflux mucosectomy is associated with better short-term symptoms than double-dose proton pump inhibitor in reflux esophagitis patients. World J Gastrointest Surg 2026; In press
Received
2026-02-11 02:36
Peer-Review Started
2026-02-11 02:52
First Decision by Editorial Office Director
2026-03-03 08:57
Return for Revision
2026-03-03 08:57
Revised
2026-03-11 11:19
Publication Fee Transferred
2026-03-12 10:09
Second Decision by Editor
2026-04-03 02:44
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director
2026-04-03 05:50
Articles in Press
2026-04-03 05:50
Edit the Manuscript by Language Editor
Typeset the Manuscript
ISSN 1948-9366 (online)
Open Access This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
Copyright ©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com